Brief: Septerna Says SEP-631 Well-Tolerated With Adverse Event Profile Comparable To Placebo

Septerna

01/03/2026 14:47

March 1 (Reuters) - Septerna Inc SEPN.O:

SEPTERNA ANNOUNCES POSITIVE PHASE 1 DATA FOR SEP-631, AN ORAL MRGPRX2 NAM FOR THE TREATMENT OF MAST CELL-DRIVEN DISEASES, AND OUTLINES INITIAL PHASE 2 DEVELOPMENT STRATEGY

SEPTERNA INC - SEP-631 WELL-TOLERATED WITH ADVERSE EVENT PROFILE COMPARABLE TO PLACEBO

SEPTERNA INC - PHASE 2 DEVELOPMENT FOR CHRONIC SPONTANEOUS URTICARIA PLANNED FOR 2026

Source text: ID:nGNXc08Sz5

Further company coverage: SEPN.O

 ((Reuters.Briefs@thomsonreuters.com;))